FDA批准口服SERD giredestrant联合依维莫司用于ESR1突变乳腺癌
Next-Generation Oral SERD Approved for Breast Cancer
FDA批准下一代口服SERD giredestrant(商品名Wilserdly)联合依维莫司,用于既往治疗过的ER阳性、HER2阴性、ESR1突变型乳腺癌患者。
原文明确给出获批适应症与III期evERA研究的关键生存数据,读者可据此判断该方案对ESR1突变人群的临床价值。
— Combination of giredestrant plus everolimus reduced risk of progression or death by 62%
November 17, 2026 • 2 min read
The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated breast cancer.
The all-oral combination is indicated for patients with locally advanced or metastatic cancer whose disease recurred during or after completion of endocrine-based adjuvant therapy or progressed on at least one endocrine-based regimen in the metastatic setting.
"As oncologists we are always looking for better and more effective treatments for patients with metastatic breast cancer, particularly when their disease progresses on endocrine therapies and CDK4/6 inhibitors," said Erica Mayer, MD, MPH, of the Dana-Farber Cancer Institute in Boston, in a press release. "Today's FDA approval of giredestrant gives patients an important new therapeutic option, which substantially improves disease control while also providing the convenience of an all-oral regimen."
Approval was based on results from the global phase III evERA study, which evaluated giredestrant plus everolimus versus standard endocrine therapy plus everolimus in patients with ER-positive, HER2-negative advanced breast cancer, more than half of whom had ESR1 mutations.
The study showed that among those with ESR1-mutated cancer, median progression-free survival (PFS) nearly doubled from 5.5 months with standard endocrine therapy to 10.0 months with giredestrant and everolimus (HR 0.38, 95% CI 0.27-0.54, P<0.001).
In the overall study population, median PFS was 8.8 months for patients receiving giredestrant plus everolimus (HR 0.56, 95% CI 0.44-0.71, P<0.001).
The most common adverse reactions in patients receiving giredestrant plus everolimus were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea, while the most common laboratory abnormalities were decreased hemoglobin, lymphocytes, white blood cell count, neutrophils, platelets, calcium, potassium, and sodium, and increased aspartate transaminase, alanine transaminase, and creatinine.
Prescribing information includes warnings and precautions for bradycardia and embryo-fetal toxicity.
The FDA also authorized the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations.
来源:MedPage Today · medpagetoday.com